ADCY9

ADCY9 encodes a transmembrane adenylyl cyclase (AC9) that generates cAMP in response to Gs-coupled receptor stimulation, functioning as a regulated signaling node in immune cells, cardiac tissue, neurons, and airway smooth muscle. Unlike other adenylyl cyclases, AC9 is insensitive to forskolin, Ca²⁺, and calcineurin inhibitors and is auto-inhibited by its isoform-specific C2b carboxyl-terminal domain, with residues 1268–1276 critical for this restraint; proteolytic removal of C2b markedly enhances cAMP output (PMID:9628827, PMID:30121334). ADCY9 expression is post-transcriptionally tuned by multiple microRNAs (miR-142-3p, miR-181a/b) whose levels set cAMP tone in regulatory T cells, leukemia differentiation, and neuropathic pain circuits (PMID:19098714, PMID:24722286, PMID:33416140). Genetic inactivation of Adcy9 in mice is atheroprotective—reducing macrophage plaque accumulation and improving endothelial vasorelaxation—and cardioprotective after myocardial infarction, benefits that are abolished when CETP is co-expressed, revealing a functionally significant ADCY9–CETP interaction axis (PMID:29674325, PMID:37054880).

1. 1998 High

   Cloning and initial characterization of human ADCY9 established that it is a β-adrenergic-responsive adenylyl cyclase with unique pharmacological properties—insensitivity to forskolin, Ca²⁺, somatostatin, and calcineurin—distinguishing it from all other AC isoforms and raising the question of how its activity is regulated.

   Evidence Heterologous expression in HEK-293 cells with pharmacological profiling and cDNA cloning

   PMID:9628827

   Open questions at the time

   • No structural basis for forskolin insensitivity
   • Endogenous regulatory partners unidentified
   • Tissue-specific splice variant function unknown
2. 2008 High

   Identification of miR-142-3p as a direct post-transcriptional repressor of ADCY9 in T cells revealed how FOXP3-dependent downregulation of this miRNA keeps the AC9/cAMP axis active in Tregs, providing the first mechanism linking ADCY9 regulation to immune suppression.

   Evidence miRNA target validation, cAMP measurement, FOXP3 knockdown/overexpression in human CD4⁺ T cells

   PMID:19098714

   Open questions at the time

   • Whether ADCY9 is the sole cAMP source mediating Treg suppression
   • Upstream signals controlling miR-142-3p beyond FOXP3
3. 2013 Medium

   Demonstration that miR-181a and miR-181b independently target ADCY9 3′UTR to reduce cAMP in leukemia and cervical cancer cells extended the miRNA regulatory network beyond T cells, linking ADCY9 suppression to proliferative and anti-apoptotic phenotypes and to impaired ATRA-induced differentiation via cAMP/PKA/RAR signaling.

   Evidence 3′UTR luciferase reporters, siRNA knockdown, cAMP assays, and ATRA differentiation assays in APL and cervical cancer cell lines

   PMID:24269684 PMID:24722286

   Open questions at the time

   • Relative contribution of miR-181a vs. miR-181b in vivo
   • Whether cAMP/PKA is the only downstream effector in these cancer contexts
4. 2018 High

   Mutagenesis of the C2b domain revealed an isoform-specific auto-inhibitory mechanism: residues 1268–1276 within the C-terminal C2b domain restrain cAMP production, and C2b deletion markedly enhances Gs-coupled responses, suggesting proteolytic cleavage as a potential activation switch in cardiac tissue.

   Evidence C2b deletion and point mutagenesis in HEK-293 stable lines with cAMP quantification and domain-specific immunoblotting

   PMID:30121334

   Open questions at the time

   • Identity of the protease cleaving C2b in vivo
   • Structural mechanism by which C2b restrains catalytic activity
   • In vivo validation of proteolytic regulation in cardiomyocytes
5. 2018 High

   Adcy9 knockout in mice demonstrated that loss of AC9 is atheroprotective—reducing macrophage accumulation, improving endothelial vasorelaxation via NO/COX/EDH pathways—and that these benefits are abolished on a CETP-transgenic background, establishing a genetically defined ADCY9–CETP interaction in cardiovascular disease.

   Evidence Adcy9 gene-trap KO mice on atherogenic diet; vasorelaxation, flow cytometry, splenocyte adhesion, MRI; epistasis with CETP transgene

   PMID:29674325

   Open questions at the time

   • Molecular mechanism of ADCY9–CETP interaction (direct vs. indirect)
   • Cell-type-specific contribution of ADCY9 to atherosclerosis
   • Whether human ADCY9 loss-of-function variants recapitulate protection
6. 2020 Medium

   Zebrafish adcy9 knockdown produced cardiac malformation, increased macrophage migration, cardiac apoptosis, and mmp9 upregulation, extending ADCY9's cardiovascular role to heart development and implicating it as a candidate gene for cardiac abnormalities in Rubinstein-Taybi syndrome.

   Evidence Zebrafish morpholino knockdown with immunofluorescence and RNA-seq

   PMID:32321550

   Open questions at the time

   • Morpholino off-target effects not fully controlled
   • Whether ADCY9 mutations are found in Rubinstein-Taybi patients
   • Mechanism linking cAMP loss to mmp9 induction
7. 2023 Medium

   Post-MI studies confirmed that Adcy9 inactivation reduces infarct size, preserves capillary density, and enhances adaptive immune responses in bone marrow, and that CETP expression again abolishes these benefits, reinforcing the CETP-dependent cardioprotective axis of ADCY9 loss.

   Evidence Adcy9 KO mice with coronary ligation MI model; echocardiography, histology, flow cytometry; CETP-transgenic epistasis

   PMID:37054880

   Open questions at the time

   • Whether cardioprotection is mediated by local (cardiomyocyte) or systemic (immune) ADCY9 loss
   • cAMP dynamics in infarcted tissue not measured directly
8. 2025 Medium

   Functional characterization of the Ile772Met polymorphism (rs2230739) showed that the Met772 variant is a loss-of-function allele that fails to prevent cytokine-driven airway smooth muscle remodeling, directly linking an ADCY9 coding variant to impaired cAMP production and asthma-related airway dysfunction.

   Evidence Wild-type vs. I772M mutant overexpression in airway smooth muscle cells, cAMP assay, airway remodeling readouts, paired with clinical FEV1/FVC data

   PMID:40816614

   Open questions at the time

   • Structural basis for loss of function by Ile772Met
   • Whether pharmacological cAMP supplementation rescues the Met772 phenotype in vivo
   • Population-level replication of the asthma association

• The molecular mechanism by which CETP reverses the cardiovascular benefits of ADCY9 loss remains unresolved, as does the identity of the protease that cleaves the auto-inhibitory C2b domain in vivo, and no high-resolution structure of full-length AC9 with C2b has been reported.
• ADCY9–CETP mechanistic link unknown
• C2b-cleaving protease unidentified
• No full-length AC9 structural model including C2b